miércoles, 7 de octubre de 2026
BuscarExplore
Via News Knowledge File

U.S. Food and Drug Administration

government agency80% conf.·synced Oct 6, 2026

U.S. federal agency responsible for regulating drugs and medical devices

59
sourced metrics
3201
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Parameter Count
6months_priority_review
Jun 15, 2026source
Ai Devices Cleared
1350devices
Feb 3, 2026source
Drug Approvals
17drugs
Jan 20, 2026⚠ sources conflictsource
Approval Decisions
32decisions
Jan 20, 2026source
Ai Device Authorizations
250devices
Sep 1, 2025source
Total Ai Devices Authorized
1247count
Jun 30, 2025source
Cardiology Ai Algorithms Total
116algorithms
May 1, 2025source
Ai Algorithms Cleared May 2025
39algorithms
May 1, 2025source
Accelerated Approvals
11drugs
Jan 1, 2025source
Approved Car T Products
7products
Jan 1, 2025source
Approved Gene Therapies Global
36products
Jan 1, 2025source
Approved Non Modified Cell Therapies
71products
Jan 1, 2025source
Biologics Approved
12biologics
Jan 1, 2025source
Fast Track Designations
18drugs
Jan 1, 2025source
First In Class Drugs
20drugs
Jan 1, 2025source
New Molecular Entities Approved
34NMEs
Jan 1, 2025source
Novel Drugs Approved
46drugs
Jan 1, 2025source
Oncology Approvals
50treatments
Jan 1, 2025source

Stated objectives

Evaluate appropriate regulatory pathway for CBD products beyond existing food and dietary supplement frameworks

source
stated

Reduce lead in fruit-based baby foods

source
target: 10 ppb by 2025-01-01 00:00:00stated

Reduce lead in root vegetables and dry infant cereals

source
target: 20 ppb by 2025-01-01 00:00:00stated

Complete regulatory review of TransCon CNP with PDUFA target action date

source
by 2026-02-28 00:00:00stated

FDA supports AI-based medical devices and healthcare digitization programs to accelerate AI integration in U.S. healthcare

source
stated

FDA aims to accelerate regenerative medicine advancement through expedited approval pathways while maintaining rigorous safety and efficacy standards

source
stated

Speed up the development of safe, effective, and innovative medical devices critical to public health through the TPLC Advisory Program Pilot

source
stated

Review CagriSema regulatory application for weight management

source
by 2026-01-01 00:00:00stated

Expedite development and review timelines of drugs that demonstrate potential to treat serious conditions through Fast Track designation program

source
stated

Set daily sodium intake target for food categories including salad dressings

source
target: 2750 mg daily, 220 mg per serving for salad dressings by 2025-01-01 00:00:00stated

Relationship graph · 3201 connections

regulates
2696
regulated by
310
approved by
65
located in
34
governs
21
subsidiary of
13
regulated
12
approved
9
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com